4 Min Read
(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, link.reuters.com/mex49s; for the Morning News Call newsletter, link.reuters.com/nex49s) Wall Street rose on Wednesday, helped by higher oil prices and gains in financial stocks ahead of Federal Reserve Chair Janet Yellen's testimony before a Congressional committee. The Dow Jones Industrial Average was up 0.04 percent at 18,235.36, the S&P 500 was down 0.03 percent at 2,159.33 and the Nasdaq Composite was down 0.03 percent at 5,304.355.
** NIKE INC, $54.51, -1.50 pct
At least six brokerages cut their price targets on the sportswear and footwear maker's stock as future orders missed analysts' estimates for the third time in a row.
** TEMPUR SEALY INTERNATIONAL INC, $58.59, -21.30 pct
** SELECT COMFORT CORP, $23.57, -6.17 pct
Tempur Sealy said it expected a 1-3 percent fall in full-year revenue from a year earlier, and cut its adjusted EBITDA forecast for the period.
** ORIGIN AGRITECH LTD, $2.76, +18.45 pct
The agricultural biotechnology company said on Tuesday that it would sell its China-based commercial corn seed production and distribution unit for about $60 mln to Beijing Shihui Agricultural Development Co Ltd.
** SAREPTA THERAPEUTICS INC, $61.97, +4.86 pct
RBC raised its price target on the drugmaker's stock to $108 from $83.
** BLACKBERRY LTD, $8.185, +3.87 pct
The company will outsource manufacturing of its once-core hardware, including its flagship smartphone, the Canadian company said as it reported another loss and sharp drop in revenue.
** AT&T INC, $40.795, -1.60 pct
UBS cut the rating on the wireless carrier's stock to "neutral".
** ANAVEX LIFE SCIENCES CORP, $4.46, +42.04 pct
** BIOGEN INC , $313.81, -0.23 pct
Anavex entered into an agreement with Biogen, under which Biogen will test Anavex's lead experimental drug, Anavex 2-73.
** GALECTIN THERAPEUTICS INC, $1.48, -40.08 pct
The drug developer said the mid-stage clinical trial evaluating the safety and tolerability of its lead drug, GR-MD-02, in 30 nonalcoholic steatohepatitis (NASH) patients with advanced fibrosis did not meet primary and secondary goals.
** ATHERSYS INC, $2.1357, +8.96 pct
The stem cell therapy developer said it had reached an agreement with the US FDA on a late-stage trial design to test its stem cell therapy for the treatment of ischemic stroke.
** HARMONIC INC, $5.595, +20.06 pct
** COMCAST CORP, $66.18, +0.02 pct
The companies entered into a warrant agreement where Comcast will be able to acquire Harmonic's common shares subject to sales of Harmonic products, including CableOS.
** TOWER SEMICONDUCTOR LTD, $15, -2.22 pct
The U.S.-listed shares of Israeli chipmaker dipped on an unregistered block sale.
** SONIC CORP, $25.73, -6.23 pct
The drive-in restaurant chain operator forecast fourth-quarter profit below analysts' expectations, hurt by lower-than-expected traffic. (Compiled by Aishwarya Venugopal in Bengaluru; Editing by Anil D'Silva)